Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study. (PubMed, Curr Oncol) - Sep 25, 2026 - P1/2 | "Berubicin is a doxorubicin analog developed to cross the blood-brain barrier...Patients received up to four 21-day cycles of rituximab, high-dose methotrexate, berubicin, and thiotepa, with between-patient and intrapatient berubicin dose escalation...Recruitment ended prematurely because berubicin became unavailable. This case series demonstrates the feasibility of MBTRIX, although the small sample and incomplete dose escalation preclude definitive conclusions regarding safety and efficacy."
Journal • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Transplantation
|
|
Alina Hnatyszyn; Ewa Borowiecka; Krzysztof Sommerfeld; Oliwia Piotrowska
|